Description: The presenters describe the process payers and employers can use to evaluate emerging medical device technologies, recent or pending FDA submissions for prescription drugs and experimental treatments that impact patient care, resource utilization and health care expenditures. Learn the process of identifying and selecting impactful treatments (Horizon Scanning) and quantifying the financial cost of new technologies before they arrive in the market. These workflows can be leveraged by actuaries, healthcare economists, clinicians and pharmacists from a payer (Commercial and Medicare) and employer perspective for self-funded plans. Walk through sample models that illustrate how costs for emerging technologies and treatments can be modeled.

Description: From a session at the Spring regional meeting of the Society of Actuaries held in Atlanta, Georgia, May 24-25, 1999 Equity-indexed products require an asset strategy that matches the equity options embedded in the liability. The panel discusses the following: A. Two asset strategies 1. Purchasing equity options that match the liability options: Is this a perfect match or are there still unhedged risks? 2. Dynamic hedging using the mathematics of “the Greeks”: Is it self-insuring? B. Accounting issues with these strategies

Description: From a session at a meeting of the Society of Actuaries held in San Diego, CA, June 22-23, 2000 A discussion of liquidity management for life insurance companies marketing institutional clients, in particular with respect to GIC contracts and Funding agreements. Topics included: · What happened at General American with their defaults on funding agreements. Why did the regulators and rating agencies miss the problems? · What was the impact of reinsurance? · What is the effect of adding institutional business such as putable funding agreements on liquidity management? · Are there prudent levels of this business that can be beneficial? · What is the effect of funding agreements with downgrade provisions on liquidity risks, and do such provisions create a preference for sophisticated institutional contract holders?

Description: This session explores where financial engineering is applied, who is “leading the charge,” and what are the current and future roles of actuaries. From the Record of the Society of Actuaries, Volume 27, No. 2, Session 55PD of the Toronto Spring Meeting.

Description: Presented at September 1994 Valuation Actuary Symposium. This session presents the approaches of a stock and a mutual company to surplus management, and the application of recent research in risk theory to surplus management.

Description: This panel of session 3PD of the Washington Annual Meeting discusses a range of topics which fall under a new professional label of financial engineer, and how this role relates to the role of the actuary. From the Record of the Society of Actuaries, Vol. 23, No. 3.

Description: Panel discusses securitization as a popular method for improving returns and clearing up balance sheets. From the Record of the Society of Actuaries, Vol. 23, No. 3., Session 74 PD of the Washington Annual Meeting

Description: Presented at May 1985 Spring Meeting. This session discussed: Relationship of pricing and valuation actuaries in Canada, Financial reporting system as an information source for product development, Interaction of the pricing actuary, valuation actuary, and investment officer in designing interest-sensitive products, Allocation impact on product development of expense, investment income, tax, and capital, Financial reporting information in changing premium rates for nonguaranteed premium products, Maintaining consistency between pricing and financial projection models, Reserve basis and nonforfeiture basis impact on product development, with special reference to lapse-sensitive products.

Description: While intended to assist health plan actuaries responsible for stress testing and ORSA filings, this session will also be informative for actuaries interested in communicating the impact of potential catastrophic events for health plans to their management and board. It will begin with a discussion of event thresholds for stress tests and their impact on capital and financial statements. Presenters will take a detailed look at several catastrophic event case studies (historical and hypothetical) in the following areas: healthcare specific (e.g. pandemic, specialty Rx), financial institution/credit market, operational/business, strategic and multi-event scenarios.</

Description: There is no “industry standard” approach to managing the vega (volatility) risk inherent in Variable Annuity Guarantees, Fixed Indexed Annuities and other equity-linked obligations. In this session, we will introduce and analyze a range of reinsurance solutions, including full vega risk retention, full vega risk transfer and more sophisticated or custom structures that split the vega risk between the insurer and the reinsurer in various ways. We will also explore other approaches in bespoke risk coverage and show the impact of different assumptions on a generic “VA Guarantee Cost Estimate” that has been developed by Munich Re.